Risk Stratification of Childhood Medulloblastoma Using Integrated Diagnosis: Discrepancies With Clinical Risk Stratification
- Author:
Hee Won CHO
1
;
Hyunwoo LEE
;
Hee Young JU
;
Keon Hee YOO
;
Hong Hoe KOO
;
Do Hoon LIM
;
Ki Woong SUNG
;
Hyung Jin SHIN
;
Yeon-Lim SUH
;
Ji Won LEE
Author Information
- Publication Type:Original Article
- From:Journal of Korean Medical Science 2022;37(7):e59-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Recent genomic studies identified four discrete molecular subgroups of medulloblastoma (MB), and the risk stratification of childhood MB in the context of subgroups was refined in 2015. In this study, we investigated the effect of molecular subgroups on the risk stratification of childhood MB.
Methods:The nCounter® system and a customized cancer panel were used for molecular subgrouping and risk stratification in archived tissues.
Results:A total of 44 patients were included in this study. In clinical risk stratification, based on the presence of residual tumor/metastasis and histological findings, 24 and 20 patients were classified into the average-risk and high-risk groups, respectively. Molecular subgroups were successfully defined in 37 patients using limited gene expression analysis, and DNA panel sequencing additionally classified the molecular subgroups in three patients. Collectively, 40 patients were classified into molecular subgroups as follows: WNT (n = 7), SHH (n = 4), Group 3 (n = 8), and Group 4 (n = 21). Excluding the four patients whose molecular subgroups could not be determined, among the 17 average-risk group patients in clinical risk stratification, one patient in the SHH group with the TP53 variant was reclassified as very-high-risk using the new risk classification system. In addition, 5 of 23 patients who were initially classified as high-risk group in clinical risk stratification were reclassified into the low- or standard-risk groups in the new risk classification system.
Conclusion:The new risk stratification incorporating integrated diagnosis showed some discrepancies with clinical risk stratification. Risk stratification based on precise molecular subgrouping is needed for the tailored treatment of MB patients.
